Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
MERIDIAN BIOSCIENCE INC (VIVO) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/01/2023 8-K Quarterly results
12/12/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
10/11/2022 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/30/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
07/29/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
04/07/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter CINCINNATI, OHIO April 7, 2022 Meridian Bioscience, Inc. , a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022. Preliminary unaudited net revenues for the second quarter of fiscal 2022 are expected to be between $109 million and $113 million, above Meridian's expectations and a record for the Company. Individually, both of the Company's segments are also expected to have record net revenues in the quarter with the Diagnostics segment net revenues expected to be between $40 million and $42 million and the Life Science segment net revenues expected to be between $69 million and..."
02/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Offer Letter",
"Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer"
02/04/2022 8-K Investor presentation, Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY",
"Conference Call Presentation"
01/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549",
"Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board"
12/02/2021 8-K Quarterly results
11/12/2021 8-K Investor presentation, Quarterly results
Docs: "MERIDIAN BIOSCIENCE REPORTS STRONG FOURTH QUARTER AND RECORD FULL-YEAR FISCAL 2021 OPERATING RESULTS AND PROVIDES FISCAL 2022 GUIDANCE",
"Conference Call Presentation"
11/10/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Meridian Bioscience Receives FDA Emergency Use Authorization for Revogene ® SARS-CoV-2 Molecular Assay"
10/29/2021 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ...
Docs: "$200,000,000 Revolving Credit Facility, Amended and Restated Credit Agreement by and among Meridian Bioscience, Inc., the Guarantors party thereto, the lenders party thereto, PNC Bank, National Association, as Administrative Agent, PNC Capital Markets LLC, as Joint Lead Arranger and Sole Bookrunner, and Fifth Third Bank, National Association, as Joint Lead Arranger and Syndication Agent"
09/01/2021 8-K Quarterly results
08/06/2021 8-K Quarterly results
08/02/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Meridian Closes Acquisition of BreathTek ® Business CINCINNATI, OHIO August 2, 2021 - Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek ® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021. Information on the financial impacts to Meridian's fiscal fourth quarter will be discussed on the quarterly earnings call scheduled for Friday August 6, 2021. About Meridian Bioscience, Inc."
07/23/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cautionary Statement Regarding Forward-Looking Statements Certain statements in this communication regarding the proposed acquisition of assets from Otsuka as described above by Meridian, including any statements regarding the synergies, benefits and opportunities of the transaction, future opportunities for the combined company and products, future financial performance and any other statements regarding Meridian's future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts are “forward-looking” statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipate,” “believe,” “ensure,” “expect..."
07/13/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Meridian Bioscience Announces Preliminary Revenue Results for Fiscal 2021 Third Quarter CINCINNATI, OHIO July 13, 2021 Meridian Bioscience, Inc. , a provider of diagnostic testing solutions and life science raw materials, today provided preliminary revenue results for its third quarter of fiscal 2021. Preliminary unaudited revenue for the third quarter of fiscal 2021 is expected to be approximately $63.5 million, below expectations. The Diagnostics segment performance was impacted negatively by recent supply chain issues with our LeadCare reagents that resulted in backorders towards the end of the quarter. The Life Science segment performance was impacted negatively by the continued reduction in demand for reagents associated with COVID-19 testing as reported widely across the industry. Me..."
06/28/2021 8-K Quarterly results
05/07/2021 8-K Quarterly results
02/23/2021 8-K/A Quarterly results
02/23/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
02/05/2021 8-K Quarterly results
01/29/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549"
01/12/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results
12/30/2020 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from Grant Thornton LLP",
"Letter from Grant Thornton LLP"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy